Ethinylestradiol /
norethisterone acetate
Combination of
EthinylestradiolEstrogen
Norethisterone acetateProgestogen
Clinical data
Trade namesEstrostep, FemHRT, Loestrin, Microgestin, others[1]
Other namesEE/NETA
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
3D model (JSmol)
  • CC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C#C.CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O
  • InChI=1S/C22H28O3.C20H24O2/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3;1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,13,17-20H,5-12H2,2-3H3;1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t17-,18+,19+,20-,21-,22-;16-,17-,18+,19+,20+/m01/s1
  • Key:GEONECATAKDDLT-JDSZYESASA-N

Ethinylestradiol/norethisterone acetate (EE/NETA), or ethinylestradiol/norethindrone acetate, is a combination of ethinylestradiol (EE) and norethisterone acetate (NETA) which is used as birth control and menopausal hormone therapy.[1][2] EE is an estrogen, while norethisterone acetate (NETA) is a progestin.[1] It is taken by mouth.[1] Some preparations of EE/NETA used in birth control additionally contain an iron supplement in the form of ferrous fumarate.[3]

In 2020, it was the 45th most commonly prescribed medication in the United States, with more than 14 million prescriptions.[4][5] It is available as a generic medication.[6]

Society and culture

Brand names

Brand names of EE/NETA include Anovlar, Blisovi, Cumorit, Estrostep, FemHRT, Fyavolv, Gildess, Junel, Larin, Leribane, Loestrin, Lo Loestrin (Lo Lo), Mibelas, Microgestin, Minastrin, Norlestrin, Primodos, Taytulla, and Tri-Legest, among others.[7]

In addition, the combination is sold in the United States under the brand name FemHRT for use in menopausal hormone therapy.[8][9][2]

See also

References

  1. 1 2 3 4 "Estrogen-Progestin Combinations Monograph for Professionals". Drugs.com. AHFS. Retrieved 28 December 2018.
  2. 1 2 Rowan JP, Simon JA, Speroff L, Ellman H (June 2006). "Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials". Clin Ther. 28 (6): 921–32. doi:10.1016/j.clinthera.2006.06.013. PMID 16860174.
  3. ↑ Willihnganz M, Clayton AD (1 May 2014). Basic Pharmacology for Nurses - E-Book. Elsevier Health Sciences. pp. 648–. ISBN 978-0-323-29309-9.
  4. ↑ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  5. ↑ "Ethinyl Estradiol; Norethindrone - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  6. ↑ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  7. ↑ "Ethinyl Estradiol and Norethindrone (Professional Patient Advice)". Drugs.com. 13 July 2019. Retrieved 10 April 2020.
  8. ↑ "Drug Approval Package: Femhrt (Norethindrone Acetate & Ethinyl Estradiol) NDA #21065". U.S. Food and Drug Administration (FDA). Retrieved 28 December 2018.
  9. ↑ "FemHRT- norethindrone acetate/ethinyl estradiol tablet". DailyMed. 14 November 2017. Retrieved 31 December 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.